Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy

Article Abstract:

Identification of human immunodeficiency virus (HIV) infection is critical from both clinical and public health perspectives. So the cost-effectiveness of voluntary HIV screening in health care settings and to assess how incorporating the costs and benefits associated with reductions in HIV transmission would influence the cost-effectiveness of a screening program.

United Kingdom, Health aspects, HIV infection, Drug therapy, HIV infections, Medical care, Cost of, Health care costs, Highly active antiretroviral therapy

---

Cost-effectiveness of implantable cardioverter-defibrillators

Article Abstract:

The cost-effectiveness of an implantable cardioverter-defibrillator (ICD) in population represented in initial prevention trials is examined. The results display a cost-effectiveness ratio below $100,000 per quality-adjusted life-years (QALY) for prophylactic insertion of an ICD in populations, which show a noticeable device-connected decrease in mortality.

Usage, Prevention, Quality of life, Implantable cardioverter-defibrillators

---

The effect of cardiac resynchronization on morbidity and mortality in heart failure

Article Abstract:

Cardiac resynchronization improves symptoms and the quality of life and also reduces complications and the risk of death among patients with heart failure and cardiac dyssynchrony. The implantation of a cardiac-resynchronization device should routinely be considered in such patients.

Science & research, Research, Heart failure, Morbidity

Similar abstracts:

• Abstracts: Increased body mass index does not alter response to initial highly active antiretroviral therapy in HIV-1-infected patients
• Abstracts: The effect of statins on HIV rebound and blips. HIV-Associated Anal Cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome?
• Abstracts: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST outcome trial. Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure
• Abstracts: National plan for pandemic flu unveiled. Health officialEs brace for flu season. Legal concerns and the influenza vaccine shortage

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.